99 related articles for article (PubMed ID: 23116168)
1. Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.
Yang J; Wang LJ; Liu JJ; Zhong L; Zheng RL; Xu Y; Ji P; Zhang CH; Wang WJ; Lin XD; Li LL; Wei YQ; Yang SY
J Med Chem; 2012 Dec; 55(23):10685-99. PubMed ID: 23116168
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel drug-resistant EGFR mutant inhibitors by in silico screening using comprehensive assessments of protein structures.
Sato T; Watanabe H; Tsuganezawa K; Yuki H; Mikuni J; Yoshikawa S; Kukimoto-Niino M; Fujimoto T; Terazawa Y; Wakiyama M; Kojima H; Okabe T; Nagano T; Shirouzu M; Yokoyama S; Tanaka A; Honma T
Bioorg Med Chem; 2012 Jun; 20(12):3756-67. PubMed ID: 22607878
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors.
Hei YY; Shen Y; Wang J; Zhang H; Zhao HY; Xin M; Cao YX; Li Y; Zhang SQ
Bioorg Med Chem; 2018 May; 26(8):2173-2185. PubMed ID: 29576272
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors.
Lei H; Fan S; Zhang H; Liu YJ; Hei YY; Zhang JJ; Zheng AQ; Xin M; Zhang SQ
Eur J Med Chem; 2020 Jan; 186():111888. PubMed ID: 31787359
[TBL] [Abstract][Full Text] [Related]
6. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
Yu Z; Boggon TJ; Kobayashi S; Jin C; Ma PC; Dowlati A; Kern JA; Tenen DG; Halmos B
Cancer Res; 2007 Nov; 67(21):10417-27. PubMed ID: 17974985
[TBL] [Abstract][Full Text] [Related]
7. Discovery of selective EGFR modulator to inhibit L858R/T790M double mutants bearing a N-9-Diphenyl-9H-purin-2-amine scaffold.
Hu J; Han Y; Wang J; Liu Y; Zhao Y; Liu Y; Gong P
Bioorg Med Chem; 2018 May; 26(8):1810-1822. PubMed ID: 29486953
[TBL] [Abstract][Full Text] [Related]
8. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
[TBL] [Abstract][Full Text] [Related]
9. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
Hao Y; Lyu J; Qu R; Tong Y; Sun D; Feng F; Tong L; Yang T; Zhao Z; Zhu L; Ding J; Xu Y; Xie H; Li H
J Med Chem; 2018 Jul; 61(13):5609-5622. PubMed ID: 29906114
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives.
Solca FF; Baum A; Langkopf E; Dahmann G; Heider KH; Himmelsbach F; van Meel JC
J Pharmacol Exp Ther; 2004 Nov; 311(2):502-9. PubMed ID: 15199094
[TBL] [Abstract][Full Text] [Related]
12. Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.
Planken S; Behenna DC; Nair SK; Johnson TO; Nagata A; Almaden C; Bailey S; Ballard TE; Bernier L; Cheng H; Cho-Schultz S; Dalvie D; Deal JG; Dinh DM; Edwards MP; Ferre RA; Gajiwala KS; Hemkens M; Kania RS; Kath JC; Matthews J; Murray BW; Niessen S; Orr ST; Pairish M; Sach NW; Shen H; Shi M; Solowiej J; Tran K; Tseng E; Vicini P; Wang Y; Weinrich SL; Zhou R; Zientek M; Liu L; Luo Y; Xin S; Zhang C; Lafontaine J
J Med Chem; 2017 Apr; 60(7):3002-3019. PubMed ID: 28287730
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors.
Zhang L; Yang Y; Zhou H; Zheng Q; Li Y; Zheng S; Zhao S; Chen D; Fan C
Eur J Med Chem; 2015 Sep; 102():445-63. PubMed ID: 26310890
[TBL] [Abstract][Full Text] [Related]
14. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines.
Liu W; Wu X; Zhang W; Montenegro RC; Fackenthal DL; Spitz JA; Huff LM; Innocenti F; Das S; Cook EH; Cox NJ; Bates SE; Ratain MJ
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6788-95. PubMed ID: 18006781
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents.
Lv PC; Li DD; Li QS; Lu X; Xiao ZP; Zhu HL
Bioorg Med Chem Lett; 2011 Sep; 21(18):5374-7. PubMed ID: 21802290
[TBL] [Abstract][Full Text] [Related]
16. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
Wong KK
Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579
[TBL] [Abstract][Full Text] [Related]
17. Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.
Coumar MS; Chu CY; Lin CW; Shiao HY; Ho YL; Reddy R; Lin WH; Chen CH; Peng YH; Leou JS; Lien TW; Huang CT; Fang MY; Wu SH; Wu JS; Chittimalla SK; Song JS; Hsu JT; Wu SY; Liao CC; Chao YS; Hsieh HP
J Med Chem; 2010 Jul; 53(13):4980-8. PubMed ID: 20550212
[TBL] [Abstract][Full Text] [Related]
18. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR.
Michalczyk A; Klüter S; Rode HB; Simard JR; Grütter C; Rabiller M; Rauh D
Bioorg Med Chem; 2008 Apr; 16(7):3482-8. PubMed ID: 18316192
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
[TBL] [Abstract][Full Text] [Related]
20. 6-Aryl and heterocycle quinazoline derivatives as potent EGFR inhibitors with improved activity toward gefitinib-sensitive and -resistant tumor cell lines.
Hamed MM; Abou El Ella DA; Keeton AB; Piazza GA; Abadi AH; Hartmann RW; Engel M
ChemMedChem; 2013 Sep; 8(9):1495-504. PubMed ID: 23847159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
